Tanya Dorff, MD

GU Oncology Now

Tanya Dorff, MD, City of Hope Comprehensive Cancer Center, explains the challenges of providing useful and accurate prognostic information to patients with mCRPC, how the prognostic model from the CALGB 90401 trial may alleviate some of those issues, and what needs to happen to move the model into standard practice.Her comments are in relation to her recent editorial in the Journal of Clinical Oncology, &ldquo;<a href="https://ascopubs.org/doi/full/10.1200/JCO.23.00374" target="_blank" rel="noopener">Incorporating Prognostic Models Into Clinical Practice for Patients With Castration-Resistant Prostate Cancer</a>.&rdquo;

Dr. Dorff on Incorporating mCRPC Prognostic Models Into Clinical Practice

Metastatic castration-resistant prostate cancer 

CRPC

Dr. Dorff explains how the prognostic model from the CALGB 90401 trial helps provide useful and accurate information to patients with mCRPC.

Dr. Dorff: Incorporating mCRPC Prognostic Models In Practice

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe